Hong Ji Adrian Tan

Title: Innovations in Cytokine Neutralization by Hong Ji Adrian Tan

Introduction

Hong Ji Adrian Tan is a prominent inventor based in Singapore, known for his groundbreaking work in the field of immunology. He has made significant contributions to the development of transgenic T cells that can effectively neutralize human cytokines, particularly IL-6, which plays a crucial role in various diseases.

Latest Patents

Tan holds a patent titled "Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells." This patent describes transgenic T cells and vectors designed to express a membrane-bound anti-IL6 (mb-alL6) single chain variable fragment (scFv). The transgenic T cells are engineered to suppress the proliferation of IL-6-dependent cells, thereby reducing IL-6 concentration. The patent also outlines bicistronic constructs that encode both mb-alL6 and an anti-CD19-41 BB-003ζ chimeric antigen receptor (CAR). These innovations are particularly beneficial in minimizing the risk of cytokine release syndrome (CRS) in cancer patients undergoing CAR T cell therapy and in treating autoimmune and inflammatory diseases.

Career Highlights

Hong Ji Adrian Tan is affiliated with the National University of Singapore, where he conducts research and develops innovative solutions in immunotherapy. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from conditions linked to cytokine activity.

Collaborations

Tan collaborates with Dario Campana, a fellow researcher, to advance the understanding and application of transgenic T cell technology in clinical settings.

Conclusion

Hong Ji Adrian Tan's contributions to the field of immunology through his innovative patent on cytokine neutralization exemplify the potential of transgenic T cells in modern medicine. His work continues to pave the way for new therapeutic strategies in treating complex diseases.